124 related articles for article (PubMed ID: 16783967)
1. Are CYP17 genotypes a biomarker for ovarian cancer in patients with cancer history in their family?
Yazici H; Tigli H; Kadehci Z; Kucucuk S; Saip P; Issever H; Ozcelik H; Dalay N
Oncol Res; 2006; 16(1):43-7. PubMed ID: 16783967
[TBL] [Abstract][Full Text] [Related]
2. Polymorphisms of the estrogen-metabolizing genes CYP17 and catechol-O-methyltransferase and risk of epithelial ovarian cancer.
Garner EI; Stokes EE; Berkowitz RS; Mok SC; Cramer DW
Cancer Res; 2002 Jun; 62(11):3058-62. PubMed ID: 12036914
[TBL] [Abstract][Full Text] [Related]
3. The CYP17A1 -34T > C polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Kaufman B; Laitman Y; Ziv E; Hamann U; Torres D; Lahad EL; Beeri R; Renbaum P; Jakubowska A; Lubinski J; Huzarski T; Tołoczko-Grabarek A; Jaworska K; Durda K; Sprudle AB; Chenevix-Trench G; Simard J; Easton DF; Antonis A; Szabo C; Friedman E
Breast Cancer Res Treat; 2011 Apr; 126(2):521-7. PubMed ID: 20798986
[TBL] [Abstract][Full Text] [Related]
4. Risk factors and prognostic factors in patients with double primary cancer: epithelial ovarian cancer and breast cancer.
Cvelbar M; Ursic-Vrscaj M; Rakar S
Eur J Gynaecol Oncol; 2005; 26(1):59-63. PubMed ID: 15755003
[TBL] [Abstract][Full Text] [Related]
5. CYP17 gene polymorphism and its association with high-risk north Indian breast cancer patients.
Chakraborty A; Murthy NS; Chintamani C; Bhatnagar D; Mohil RS; Sharma PC; Saxena S
J Hum Genet; 2007; 52(2):159-165. PubMed ID: 17235448
[TBL] [Abstract][Full Text] [Related]
6. [Clinical significance and distribution of BRCA genes mutation in sporadic high grade serous ovarian cancer].
Liu WL; Wang ZZ; Zhao JZ; Hou YY; Wu XX; Li W; Dong B; Tong TT; Guo YJ
Zhonghua Fu Chan Ke Za Zhi; 2017 Jan; 52(1):26-31. PubMed ID: 28190312
[No Abstract] [Full Text] [Related]
7. Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations.
Gallardo M; Silva A; Rubio L; Alvarez C; Torrealba C; Salinas M; Tapia T; Faundez P; Palma L; Riccio ME; Paredes H; Rodriguez M; Cruz A; Rousseau C; King MC; Camus M; Alvarez M; Carvallo P
Breast Cancer Res Treat; 2006 Jan; 95(1):81-7. PubMed ID: 16261400
[TBL] [Abstract][Full Text] [Related]
8. A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population.
Belanger MH; Dolman L; Arcand SL; Shen Z; Chong G; Mes-Masson AM; Provencher D; Tonin PN
J Ovarian Res; 2015 Mar; 8():1. PubMed ID: 25884701
[TBL] [Abstract][Full Text] [Related]
9. The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer.
Haiman CA; Stampfer MJ; Giovannucci E; Ma J; Decalo NE; Kantoff PW; Hunter DJ
Cancer Epidemiol Biomarkers Prev; 2001 Jul; 10(7):743-8. PubMed ID: 11440959
[TBL] [Abstract][Full Text] [Related]
10. Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status.
Kotsopoulos J; Rosen B; Fan I; Moody J; McLaughlin JR; Risch H; May T; Sun P; Narod SA
Gynecol Oncol; 2016 Jan; 140(1):42-7. PubMed ID: 26556769
[TBL] [Abstract][Full Text] [Related]
11. CYP17 genotype is associated with short menstrual cycles, early oral contraceptive use and BRCA mutation status in young healthy women.
Henningson M; Johansson U; Borg A; Olsson H; Jernström H
Mol Hum Reprod; 2007 Apr; 13(4):231-6. PubMed ID: 17307805
[TBL] [Abstract][Full Text] [Related]
12. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
Pal T; Permuth-Wey J; Betts JA; Krischer JP; Fiorica J; Arango H; LaPolla J; Hoffman M; Martino MA; Wakeley K; Wilbanks G; Nicosia S; Cantor A; Sutphen R
Cancer; 2005 Dec; 104(12):2807-16. PubMed ID: 16284991
[TBL] [Abstract][Full Text] [Related]
13. CYP17 (T-34C) and CYP19 (Trp39Arg) polymorphisms and their cooperative effects on breast cancer susceptibility.
Tüzüner BM; Oztürk T; Kisakesen HI; Ilvan S; Zerrin C; Oztürk O; Isbir T
In Vivo; 2010; 24(1):71-4. PubMed ID: 20133979
[TBL] [Abstract][Full Text] [Related]
14. CYP17 promoter polymorphism and breast cancer in Australian women under age forty years.
Spurdle AB; Hopper JL; Dite GS; Chen X; Cui J; McCredie MR; Giles GG; Southey MC; Venter DJ; Easton DF; Chenevix-Trench G
J Natl Cancer Inst; 2000 Oct; 92(20):1674-81. PubMed ID: 11036113
[TBL] [Abstract][Full Text] [Related]
15. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.
Dann RB; DeLoia JA; Timms KM; Zorn KK; Potter J; Flake DD; Lanchbury JS; Krivak TC
Gynecol Oncol; 2012 Jun; 125(3):677-82. PubMed ID: 22406760
[TBL] [Abstract][Full Text] [Related]
16. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
17. Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study.
Piek JM; Torrenga B; Hermsen B; Verheijen RH; Zweemer RP; Gille JJ; Kenemans P; van Diest PJ; Menko FH
Fam Cancer; 2003; 2(2):73-8. PubMed ID: 14574155
[TBL] [Abstract][Full Text] [Related]
18. Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer.
Wenham RM; Schildkraut JM; McLean K; Calingaert B; Bentley RC; Marks J; Berchuck A
Clin Cancer Res; 2003 Oct; 9(12):4396-403. PubMed ID: 14555511
[TBL] [Abstract][Full Text] [Related]
19. Hereditary ovarian cancer.
Prat J; Ribé A; Gallardo A
Hum Pathol; 2005 Aug; 36(8):861-70. PubMed ID: 16112002
[TBL] [Abstract][Full Text] [Related]
20. Selecting Patients with Ovarian Cancer for Germline BRCA Mutation Testing: Findings from Guidelines and a Systematic Literature Review.
Eccles DM; Balmaña J; Clune J; Ehlken B; Gohlke A; Hirst C; Potter D; Schroeder C; Tyczynski JE; Gomez Garcia EB
Adv Ther; 2016 Feb; 33(2):129-50. PubMed ID: 26809252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
